rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Geron Corporation

GERN · Nasdaq

Health CareBiotechnologyNot moving yet

GERN stood above a rising 150-day average in 18 of the last 52 weekly readings, and has been out of that trend for the last 7 weeks. It is 17.4% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 7
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$38K
Officials’ trades on record
0
Institutions holding
247 (+8)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 18 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$197KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1
WhoDidSharesTraded
Michelle RobertsonEVP, CHIEF FINANCIAL OFFICERsold9,855at $1.9418 Feb 2026filed 19 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders247+8 on the quarter
New · exited38 · 31
Reported value$613.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202649,115,571$62.9M+1,795,792+3.8%
RA CAPITAL MANAGEMENT, L.P.reduced · filed 14 Aug 202642,809,751$54.8M-20,961,615−32.9%
Soleus Capital Management, L.P.added · filed 11 Aug 202642,808,659$54.8M+1,300,000+3.1%
STATE STREET CORPadded · filed 7 Aug 202635,856,671$45.9M+5,359,488+17.6%
CITADEL ADVISORS LLCadded · filed 14 Aug 202629,038,928$37.2M+7,462,359+34.6%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202627,250,215$34.9M+581,186+2.2%
Clearbridge Investments, LLCadded · filed 13 Aug 202619,648,853$25.2M+28,533+0.1%
Eversept Partners, LPreduced · filed 14 Aug 202618,717,422$24.0M-117,461−0.6%
GOLDMAN SACHS GROUP INCadded · filed 14 Aug 202616,633,368$21.3M+5,456,777+48.8%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202614,555,954$18.6M+885,169+6.5%
31 Mar 2023 – 30 Jun 2026
158204249Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Robert J. Spiegel Company insiderDirector · last 30 Sep 20260 · 1
Dawn Carter Bir Company insiderDirector · last 20 May 20260 · 0
Elizabeth G. O'Farrell Company insiderDirector · last 20 May 20263 · 0
John F. McDonald Company insiderDirector · last 20 May 20260 · 0
Susan Molineaux Company insiderDirector · last 20 May 20260 · 1
Timothy Williams Company insiderEVP and Chief Legal Officer · last 13 Apr 20260 · 0
Constantine Chinoporos Company insiderDirector · last 25 Mar 20260 · 0
Patricia S. Andrews Company insiderDirector · last 25 Mar 20260 · 0
Michelle Robertson Company insiderEVP, CHIEF FINANCIAL OFFICER · last 18 Feb 20260 · 1
Joseph Eid Company insiderEVP, R&D; Chief Medical Office · last 17 Feb 20260 · 0
Ahmed Elnawawi Company insiderEVP, Chief Commercial Officer · last 20 Oct 20250 · 0
Harout Semerjian Company insiderPresident and CEO · last 7 Aug 20250 · 0

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-14.9%
Debt to equityFY 2025 · to 31 Dec 20250.53×
Share count trendFY 2025 · to 20 Feb 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$77.6M

Analyst forecasts

No analyst forecasts yet.